checkAd
    Startseite > Aktien > AnaptysBio > Nachrichten
    AnaptysBio Aktie
    26,02
     
    USD
    +6,90 %
    +1,68 USD
    Letzter Kurs 01.05.24 Nasdaq
    25,95
     
    USD
    800 STK
    Geldkurs 01.05.24
    25,99
     
    USD
    100 STK
    Briefkurs 01.05.24
    ISIN: US0327241065 · WKN: A2AJ8C · SYM: ANAB · USA

    Neueste Nachrichten

    Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    11.03.24 · globenewswire · AnaptysBio
    Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
    29.02.24 · globenewswire · AnaptysBio
    Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · AnaptysBio
    Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
    27.11.23 · globenewswire · AnaptysBio
    Anaptys Named a BioSpace 2024 Best Places to Work Winner
    07.11.23 · globenewswire · AnaptysBio
    Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
    02.11.23 · globenewswire · AnaptysBio
    Anaptys Announces Participation in November Investor Conferences
    01.11.23 · globenewswire · AnaptysBio
    Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
    11.10.23 · globenewswire · AnaptysBio
    Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
    09.10.23 · globenewswire · AnaptysBio
    Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
    09.10.23 · globenewswire · AnaptysBio
    AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
    18.09.23 · globenewswire · AnaptysBio
    AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
    12.09.23 · globenewswire · AnaptysBio